In the latest assessment following prior reviews like the 2025 Annals analysis showing limited THC benefits, a Cochrane review finds cannabis-based medicines offer no clinically meaningful relief for chronic neuropathic pain versus placebo. Analyzing 21 randomized trials with over 2,100 adults, it reports no high-quality evidence of effectiveness, with only minor, insignificant improvements from THC-CBD combinations.
Neuropathic pain remains challenging to treat, prompting scrutiny of cannabis-based options.
This updated Cochrane review, published in 2026, examined 21 randomized clinical trials (2-26 weeks duration) comparing THC-dominant, CBD-dominant, and THC-CBD products against placebos.
Findings showed no reliable pain reduction beyond placebo. THC-CBD combinations yielded slight patient-reported benefits, but these were not clinically significant. Adverse effect data was low-quality, with THC products linked to more dizziness, drowsiness, and dropouts.
Lead author Winfried Häuser from Technische Universität München stressed: "We need larger, well-designed studies with a treatment duration of at least 12 weeks that include people with comorbid physical illnesses and mental health conditions to fully understand the benefits and harms of cannabis-based medicines." He noted most trials' poor quality prevents firm conclusions.
The review reinforces the weak evidence base, urging better research before clinical recommendations.
